United States Patent 11,576,907 (Scope of Claims and U.S. Patent Landscape)
U.S. Patent 11,576,907 covers a specific chiral (R)-pyrazolo[3,4-g]isoquinoline small-molecule scaffold bearing (i) a substituted pyridine-2-yl methanone motif and (ii) sulfonyl-linked heteroaryl aryl groups, plus downstream claims to pharmaceutical compositions and methods of modulating the glucocorticoid receptor (GR). The claim set is primarily structure-based (compound formula claims) with functional downstream coverage limited by those same structural constraints (composition and GR modulation method claims that require the claimed compound(s) or salts).
What is the claimed chemical scope of US 11,576,907 (structure limits and stereochemistry)?
Core scope: a single stereodefined compound identity (and close structural variants) centered on a constrained bicyclic “hexahydro-1H-pyrazolo[3,4-g]isoquinoline” system with:
- Chirality: an (R) stereochemical designation at the stated chiral center (“(R)-( … )”).
- Ar–CO–(pyridine-2-yl) motif: the scaffold is substituted with a pyridine-2-yl methanone group attached at the indicated position (in your text: “(4-(trifluoromethyl)pyridine-2-yl)methanone”).
- Sulfonyl linker: the “6-((… )sulfonyl)” portion binds a substituted aromatic/heteroaryl group through sulfonyl.
- Aryl substitution set: examples you provided include:
- (4-fluorophenyl) on the 1-position phenyl group
- (4-(trifluoromethyl)pyridine-2-yl) as the methanone aryl
- sulfonyl aryl/heteroaryl variants: (i) 1-methyl-1H-pyrazol-4-yl, (ii) (2-methyl-2H-1,2,3-triazol-4-yl), and (iii) the alternative formatting in dependent claim 4 indicating an aryl substitution pattern that appears to be another variant of the sulfonyl-linked group.
How does the patent treat stereochemistry (R vs other enantiomers)?
Claim 1 and the variant compound claim(s) explicitly recite (R)-. That is a meaningful scope limiter:
- Coverage is directed to the R-enantiomer rather than “a racemate” or “both enantiomers,” unless the specification broadens it (not provided in your extract).
- Any generic design that uses an enantiomerically enriched S form or racemic formulation can create a non-infringement argument if the asserted formulation does not contain the claimed R compound in an infringement-relevant way. Whether that argument succeeds depends on the exact claim language in the issued patent text (not supplied in full here).
What is the “hexahydro-pyrazolo[3,4-g]isoquinoline” scaffold doing in claim scope?
The scaffold is structurally narrow because it requires:
- a fused ring system with specific saturation (“hexahydro”),
- a specific ring fusion pattern (“pyrazolo[3,4-g]isoquinoline”),
- and substitution at the indicated ring positions (as encoded by the formula).
In practice, that limits “workarounds” that try to keep only the GR-binding pharmacophore while changing the heterobicyclic core. A competitor would likely need to keep the core scaffold to fall within the literal formula constraints.
Which claim elements expand beyond the single compound (and what is actually broadened)?
From the claim text you supplied, the set is layered as follows:
Claim 1 (independent compound formula)
Covers the specific (R)-compound with:
- 4-fluorophenyl at the indicated position,
- sulfonyl substituent: 1-methyl-1H-pyrazol-4-yl,
- methanone aryl: 4-(trifluoromethyl)pyridine-2-yl.
Claim 2 (pharmaceutical composition)
Covers a composition comprising:
- a pharmaceutically acceptable excipient,
- and “a compound having the formula.”
This is not composition-by-process; it is composition-by-active. The active must satisfy the formula scope.
Claim 3 (method of modulating GR)
Covers a GR modulation method:
- contacting a GR with “a compound having the formula,”
- thereby modulating GR.
This is still structurally anchored: a method claim can be infringed only if the contacting compound meets the formula (or salt) requirement.
Claim 4 (dependent compound variant)
Claim 4 recites a different compound formula variant:
- still the same (R)-pyrazolo[3,4-g]isoquinoline “hexahydro” core family,
- still the pyridine-2-yl methanone with (4-(trifluoromethyl)pyridine-2-yl),
- but modifies the sulfonyl-linked group from the 1-methyl-1H-pyrazol-4-yl substituent to a different substituent pattern shown in your text (the text you pasted includes a compound string that is harder to parse because it alternates between a “6- … sulfonyl” and an “6- … phenyl)sulfonyl” formatting). The intent is clear: a structural variant at the sulfonyl-linked heteroaryl/aryl position.
Claims 5-6 (further narrowing to another sub-variant + composition)
Claims 5 and 6 follow the same pattern:
- Claim 5 further specifies the compound within the Claim 4 family (additional formula details).
- Claim 6 covers composition with that specified sub-variant or its salt.
Claims 7 and 10 (method of modulating GR)
Claims 7 and 10 mirror Claims 3 and another GR method variant:
- contacting GR with the specified compound (or salt),
- thereby modulating GR.
Claim 8-9 (another compound variant + composition)
Your text indicates Claim 8 is a further sulfonyl-linked heteroaryl replacement:
- sulfonyl group: (2-methyl-2H-1,2,3-triazol-4-yl),
- otherwise the same core and pyridine-2-yl methanone motif.
Claim 9 then provides the composition coverage for that Claim 8 compound.
Net result: what is broadened vs narrowed?
- The broadest coverage is Claims 1 and 2/3 for the specific sulfonyl heteroaryl variant in Claim 1.
- The remaining claims expand coverage to additional sulfonyl-linked substituent variants (Claims 4-5 and 8) and corresponding compositions and GR modulation methods.
- There is no evidence in your provided claim text of a large “Markush” range of substituents; coverage looks variant-specific rather than open-ended.
What does the GR modulation method claim practically cover (and where are the infringement hotspots)?
Claim 3 / 7 / 10 are functional but tied to a structure:
- infringement depends on whether the accused product contains or is used to deliver a compound that meets the claimed formula and enantiomeric requirement, and
- whether the claimed “contacting a glucocorticoid receptor” occurs in a real-world use scenario.
Key commercial/legal implications:
- Labeling and use instructions matter: if the GR-modulating compound is used for conditions where GR modulation is the mechanism, the method claim risk rises.
- Generic “same compound” products carry method exposure in addition to composition exposure, because method claims are not limited to formulation. A generic manufacturer could still face method infringement if it sells the same active and the drug is used in a manner that satisfies the “contacting” step with the claimed compound.
- Salt forms: your text mentions “or a pharmaceutically acceptable salt.” If the issued claims include salts broadly, salt switching is less likely to avoid infringement (again dependent on full claim language in the issued patent).
How many distinct compound families are claimed in US 11,576,907 (based on your claim set)?
From the text provided, there are at least three distinct compound embodiments:
- Claim 1 compound: sulfonyl-linked 1-methyl-1H-pyrazol-4-yl variant.
- Claim 4/5 compound: sulfonyl-linked different aryl/heteroaryl variant (format suggests another substitution pattern at the sulfonyl-linked group).
- Claim 8 compound: sulfonyl-linked 2-methyl-2H-1,2,3-triazol-4-yl variant.
Each has corresponding:
- composition claims (Claims 2, 6, 9), and
- GR modulation method claims (Claims 3, 7, 10).
What is the likely patent estate architecture around US 11,576,907 (compound vs formulation vs use)?
Given only the issued claim excerpt you provided, the estate for this technology class typically breaks into layers:
Layer 1: Core scaffold compounds
- independent compound formula claims (here, at least Claim 1).
- stereochemistry likely repeated across family members.
Layer 2: Variant sulfonyl substituents
- dependent compound claims that cover alternative heteroaryl/aryl sulfonyl substituents (Claims 4/5 and 8).
Layer 3: Downstream uses
- method-of-use claims limited to GR modulation via contacting GR with the claimed compound.
Layer 4: Pharmaceutical compositions
- basic composition claims with excipients and the compound (Claims 2/6/9).
What is not evidenced in your excerpt:
- dedicated formulation patents (e.g., specific polymorphs, particle sizes, crystalline forms, specific oral solid dispersion constructs),
- manufacturing methods (not shown),
- or broad genus “any sulfonyl heteroaryl” Markush claims.
What generic entry risks exist for products containing the same R-enantiomer and scaffold?
For a generic competitor, the dominant infringement pathway is straightforward:
- if the ANDA/505(b)(2) product uses the same active compound (including enantiomeric form) and salts that fall within the formula, composition and method claims are both at risk.
Primary risk vectors:
- Active ingredient identity: the generic must match the claimed chemical identity, including stereochemistry, if that is required for literal infringement.
- Salt selection: if the claims expressly cover “pharmaceutically acceptable salts,” salt switching is harder.
- Mechanism-based use: if the generics are marketed with GR-relevant indications or used clinically in a way that satisfies “contacting GR,” method claims add leverage for settlement.
Practical litigation posture for a brand:
- enforce composition claims as a cleaner infringement theory (selling a formulation containing the claimed compound),
- then use method claims as additional settlement pressure if the labeling/clinical use aligns with GR modulation.
What FDA Orange Book status would matter most for US 11,576,907 (and how does it drive Paragraph IV leverage)?
US 11,576,907 is not, by itself, enough to map to an Orange Book record without the branded drug name, NDA/BLA number, and the patent listing text. In a typical Orange Book workflow:
- compound and composition patents are often listed as “Drug Substance” or “Drug Product” patents,
- method-of-use patents are listed as “Use” patents tied to approved indications.
If this patent is listed:
- the listed patent type would determine whether generic challenges typically target the same patent entry (and which claim(s) are asserted in Paragraph IV suits),
- method claims may be asserted if the challenged generic is approved for the same labeled indication.
What patent expiration and exclusivity timeline should be modeled for enforcement (how to think about last-to-expire)?
A reliable timeline requires the application filing dates, priority chain, and issued/patent term adjustments. Your prompt does not include:
- earliest non-provisional filing date,
- patent issue date,
- PTA and PTE,
- any patent term extension.
Without those, the only defensible statement is structural:
- the enforcement window for this patent ends when it expires (or is terminally disclaimed), while FDA regulatory exclusivities (180-day exclusivity for first Paragraph IV filer; pediatric exclusivity; orphan exclusivity; RDP exclusivity for biologics) are separate clocks.
How strong is the patent estate around US 11,576,907 (claim tightness vs design-around feasibility)?
Based on claim structure alone:
- Strength factor (pro-brand): the claims are highly specific: a defined fused scaffold, defined substitution pattern, and explicit (R) stereochemistry. That narrows obvious design-arounds that try to preserve only the general GR pharmacology.
- Strength factor (pro-brand): the claim set includes both composition and method claims, enabling multiple infringement theories.
- Design-around pressure (anti-brand for enforceability): if competitors change the sulfonyl-linked heteroaryl substituent, or swap the enantiomer, they may escape literal coverage. Whether they can do so while preserving GR activity and other developability constraints is an engineering question, but the legal scope is not a broad genus.
What claims and scope would likely be targeted in litigation for US 11,576,907?
In typical enforcement of compound-and-use families:
- Assert composition claims (Claims 2/6/9) because infringement can be tied to the presence of the active in marketed drug product.
- Assert compound claims (Claim 1 and the variant compound claims) when discovery can establish API identity.
- Assert method claims (Claims 3/7/10) when the brand can map labeled or actual clinical use to GR modulation with the claimed compound.
The most litigation-sensitive element is the compound formula. If the accused product uses a close analog with a different sulfonyl substituent or different stereochemistry, the infringement battle shifts to chemical proof and claim construction.
Key Takeaways
- US 11,576,907 is a structure-defined patent centered on an (R)-hexahydro-pyrazolo[3,4-g]isoquinoline scaffold with pyridine-2-yl methanone and sulfonyl-linked heteroaryl/aryl substituents.
- The claim set covers:
- specific compound embodiments (at least three distinct sulfonyl-linked variants in your text),
- pharmaceutical compositions containing those compounds (with excipients, including salts),
- methods of modulating the glucocorticoid receptor by contacting GR with the claimed compounds.
- Design-around risk concentrates on:
- changing the R stereochemistry,
- changing the sulfonyl-linked substituent outside the claimed variants,
- using different salt/enantiomer preparations if claims allow avoidance.
- Enforceability leverage is enhanced by the dual composition + method claim coverage, but the scope is tight enough that “near neighbors” may reduce literal infringement exposure.
FAQs
1) Does US 11,576,907 cover racemic mixtures or only the (R)-enantiomer?
Your provided claims require an (R)- designation for the covered compounds, which narrows literal coverage to the R-enantiomer unless the full specification/claims include broader enantiomer definitions.
2) Are glucocorticoid receptor modulation method claims limited to a specific therapeutic indication?
Your claim text is mechanism-based (“modulating a glucocorticoid receptor”) and is not tied in the excerpt to a named indication, but real-world infringement depends on whether the claimed compound is used in a way that satisfies the “contacting” step.
3) Can a generic avoid infringement by using a different salt form of the same compound?
If the claims expressly include “pharmaceutically acceptable salt thereof” (as your text indicates), salt switching is less likely to avoid literal coverage.
4) How do sulfonyl substituent changes affect design-around strategy?
Your claim set appears variant-specific at the sulfonyl-linked group. Changing that heteroaryl/aryl substituent can be a direct path out of literal scope.
5) Would changing the core scaffold (pyrazolo[3,4-g]isoquinoline) avoid both composition and method claims?
Yes in principle, because both composition and method claims are anchored to “a compound having the formula,” which requires the claimed scaffold and substitution pattern.
References
- United States Patent 11,576,907, “(R)-(1-(4-fluorophenyl)-6-...-pyridine-2-yl)methanone” (as provided via claim text).
